Evidence map›Paper›PMID 38379061›Full record

ArticleInternational journal of legal medicine2024

Forensic application of three interstitial pneumonia markers: search for new pneumonia markers in dead bodies.

Keisuke Okaba, Go Inokuchi, Kie Horioka, Hirotaro Iwase, Hiroyuki Inoue, Ayumi Motomura, Namiko Ishii, Chihiro Moue, Takayuki Shiomi, Daisuke Yajima

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of legal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Keisuke OkabaDepartment of Forensic Medicine, School of Medicine, International University of Health and Welfare, Narita, Japan. k.okaba@iuhw.ac.jp.ORCID http://orcid.org/0000-0002-5420-0978
Go InokuchiDepartment of Legal Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Kie HoriokaDepartment of Forensic Medicine, School of Medicine, International University of Health and Welfare, Narita, Japan.
Hirotaro IwaseDepartment of Legal Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hiroyuki InoueDepartment of Forensic Medicine, School of Medicine, International University of Health and Welfare, Narita, Japan.
Ayumi MotomuraDepartment of Forensic Medicine, School of Medicine, International University of Health and Welfare, Narita, Japan.
Namiko IshiiDepartment of Forensic Medicine, School of Medicine, International University of Health and Welfare, Narita, Japan.
Chihiro MoueDepartment of Forensic Medicine, School of Medicine, International University of Health and Welfare, Narita, Japan.
Takayuki ShiomiDepartment of Pathology, School of Medicine, International University of Health and Welfare, Narita, Japan.
Daisuke YajimaDepartment of Forensic Medicine, School of Medicine, International University of Health and Welfare, Narita, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In forensic cases, detailed identification of pneumonia is important. Our objective was to statistically determine the applicability of three interstitial lung disease (ILD) markers for forensic diagnosis using serum collected from dead bodies with various postmortem intervals (PMIs). We retrospectively analyzed the levels of postmortem serum Krebs von den Lungen-6 (KL-6) and pulmonary surfactant-associated proteins A and D (SP-A and SP-D) using 221 samples obtained during forensic autopsy at our facility from 2019 to 2023. We evaluated the diagnostic efficacy of ILD markers for various pneumonias against the pathological diagnosis, and examined the assessment of the severity of ILD. When comparing the ILD group with bacterial pneumonia (BP) versus the control group, there was a significant increase in KL-6 in the ILD group. When comparing the severe ILD (SILD) group with the mild ILD (MILD) group, there was a significant increase in KL-6 and SP-D in the SILD group. The optimal cutoff values for differentiating SILD were 607.0 U/mL for KL-6, 55.5 ng/mL for SP-A, and 160.0 ng/mL for SP-D, and the sensitivity/specificity (%) of KL-6, SP-A, and SP-D for SILD were 84.1/95.2, 55.6/85.7, and 66.7/74.6, respectively. This is the first study to examine KL-6 in postmortem serum in forensic medicine. By analyzing dead bodies with various PMIs, our results confirmed statistically that postmortem serum KL-6 specifically detects ILD, postmortem serum SP-A has high sensitivity to lung injury, and postmortem serum SP-D is potentially useful in assessing the severity of ILD.

Indexed as

BiomarkersLung Diseases, InterstitialMucin-1Pulmonary Surfactant-Associated Protein APulmonary Surfactant-Associated Protein DAdultAgedAged, 80 and overFemaleForensic PathologyHumansMaleMiddle AgedPneumoniaPneumonia, BacterialRetrospective StudiesBiomarkersMUC1 protein, humanMucin-1Pulmonary Surfactant-Associated Protein APulmonary Surfactant-Associated Protein DCOVID-19 pneumoniaForensic autopsyInterstitial lung diseaseKL-6SP-ASP-D

Identifiers

PMID38379061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.